Cingulate Inc. $CING

What the company doesAI summary of filing

Cingulate Inc. is a clinical-stage biopharmaceutical company developing a pipeline of pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform technology. The company's lead candidate, CTx-1301 (dexmethylphenidate), is in regulatory review with an NDA submitted to the FDA in July 2025 for the treatment of attention deficit/hyperactivity disorder (ADHD) across children, adolescents, and adults; the FDA assigned a PDUFA target action date of May 31, 2026. The company also develops CTx-1302 (dextroamphetamine) for ADHD and CTx-2103 (buspirone) for anxiety, both pending additional capital resources for clinical development. Cingulate does not currently generate revenue and makes money through its development programs and potential future commercialization arrangements, such as its agreements with Indegene and IQVIA for CTx-1301 commercialization services pending FDA approval. [10-K 2026-03-18]

Segments: CTx-1301 (dexmethylphenidate for ADHD), CTx-1302 (dextroamphetamine for ADHD), CTx-2103 (buspirone for anxiety)